RNA5SP201: A Potential Drug Target and Biomarker (G100873462)

Target Name: RNA5SP201

NCBI ID: G100873462

RNA5SP201

Other Name(s): RNA, 5S ribosomal pseudogene 201 | RN5S201

RNA5SP201: A Potential Drug Target and Biomarker

RNA5SP201 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in the development, maintenance, and progression of cancer. RNA5SP201 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Its potential as a drug target makes it an attractive target for cancer researchers and pharmaceutical companies. In this article, we will discuss the biology of RNA5SP201, its potential as a drug target, and its potential as a biomarker.

The biology of RNA5SP201

RNA5SP201 is a non-coding RNA molecule that is approximately 190 nucleotides in length. It is expressed in various types of cells and is involved in the regulation of the cell cycle. The cell cycle is the process by which a cell grows, replicates its DNA, and divides. RNA5SP201 is a key regulator of the cell cycle by controlling the entry and exit of RNA molecules at the stage of the cell cycle where they are involved in the development and progression of cancer.

RNA5SP201 has been shown to be involved in the regulation of various cell cycle processes, including G1 phase, S phase, and G2 phase. It has been shown to play a role in the maintenance of the G1 phase by regulating the amount of nuclear protein at the nuclear membrane. It has also been shown to regulate the expression of genes involved in cell cycle progression, such as the cyclin D1 gene.

In addition to its role in the cell cycle, RNA5SP201 has also been shown to be involved in the regulation of cell survival and angiogenesis. It has been shown to play a role in the regulation of cell survival by regulating the expression of genes involved in cell apoptosis, such as the Bax gene. It has also been shown to play a role in the regulation of angiogenesis by regulating the expression of genes involved in blood vessel formation and maintenance, such as the Ets gene.

Potential as a drug target

RNA5SP201's potential as a drug target is based on its involvement in the regulation of the cell cycle and its involvement in the development and progression of cancer. Drugs that target RNA5SP201 have the potential to inhibit its activity and disrupt its regulation of the cell cycle. This could lead to the inhibition of cell growth, division, and apoptosis, which could be beneficial in the treatment of cancer.

RNA5SP201 has been shown to interact with several drug targets, including the inhibitor of the DNA damage-inducible gene 1 (IDG1) gene. IDG1 is a key regulator of the cell cycle and has been shown to play a role in the development and progression of cancer. Drugs that target IDG1, such as the drug NEDD8A, have been shown to inhibit the activity of RNA5SP201 and disrupt its regulation of the cell cycle.

RNA5SP201 has also been shown to interact with the transcription factor p21.p53, which is involved in the regulation of apoptosis. p21.p53 is a negative regulator of apoptosis and has been shown to play a role in the regulation of cell survival. Drugs that target p21.p53, such as the drug p53, have been shown to inhibit the activity of RNA5SP201 and disrupt its regulation of the cell cycle.

Potential as a biomarker

RNA5SP201 has also been shown to have potential as a biomarker for cancer. Its expression has been shown to be highly correlated with the

Protein Name: RNA, 5S Ribosomal Pseudogene 201

The "RNA5SP201 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5SP201 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets